# Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

> **NCT00559975** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 60 (estimated)

## Conditions studied

- Influenza Infection

## Interventions

- **BIOLOGICAL:** Subunit influenza vaccine
- **BIOLOGICAL:** Adjuvanted influenza vaccine
- **BIOLOGICAL:** Adjuvanted influenza vaccine combined with CpG7909
- **BIOLOGICAL:** Adjuvanted influenza vaccine combine with CpG7909
- **BIOLOGICAL:** Adjuvanted influenza vaccine combine with CpG7909

## Key facts

- **NCT ID:** NCT00559975
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** —
- **Final completion:** 2008-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2009-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00559975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00559975, "Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00559975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*